Elevated nuclear YBX1 expression and the clinicopathological characteristics of patients with solid tumors: a meta-analysis

Purpose: Y-box binding protein 1 (YBX1) is a multifunctional protein linked to tumor progression and its elevated expression is an indicator of poor prognosis in various cancers. This meta-analysis aimed to investigate the prognostic value and clinical significance of YBX1 in malignant cancer. Methods: Relevant articles published through September 12, 2018 were identified from a comprehensive electronic and manual search in PubMed, Web of Science and Embase databases. The combined odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95% CIs) were used to estimate the relationship among clinicopathological characteristics, overall survival and disease-free-survival of patients with solid tumor and YBX1 expression. Results: The study included 27 studies and 5,996 patients. Our analysis revealed significant association between increased YBX1 expression and tumor differentiation status, tumor size and lymph node metastasis; moreover, the pooled HR values demonstrated that high nuclear YBX1 expression was significantly associated with worse overall survival (HR=2.14; 95% CI: 1.72–2.67, P<0.001). Conclusion: The evidence supports YBX1 as a tumor biomarker to guide clinical management and indicate prognosis.

[1]  Jifeng Feng,et al.  High YBX1 expression indicates poor prognosis and promotes cell migration and invasion in nasopharyngeal carcinoma , 2017, Experimental cell research.

[2]  J. Tamaru,et al.  Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer. , 2017, International journal of oncology.

[3]  R. Ni,et al.  Hyper-O-GlcNAcylation of YB-1 affects Ser102 phosphorylation and promotes cell proliferation in hepatocellular carcinoma. , 2016, Experimental cell research.

[4]  T. Sudo,et al.  Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer. , 2016, Anticancer research.

[5]  T. Guo,et al.  High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma , 2016, OncoTargets and therapy.

[6]  N. Osman,et al.  Golgi Phosphoprotein-3 and Y-Box-Binding Protein-1 Are Novel Markers Correlating With Poor Prognosis in Prostate Cancer. , 2016, Clinical genitourinary cancer.

[7]  Anbok Lee,et al.  The value of cytoplasmic Y-box-binding protein 1 as a prognostic marker for breast cancer in Korean , 2015, Breast Cancer.

[8]  Yunde Liu,et al.  Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas , 2015, Tumor Biology.

[9]  Xuebing Yan,et al.  High expression of Y-box-binding protein 1 is associated with local recurrence and predicts poor outcome in patients with colorectal cancer. , 2014, International journal of clinical and experimental pathology.

[10]  Zhenhuan Zhao,et al.  Association between higher expression of YB-1 and poor prognosis in early-stage extranodal nasal-type natural killer/T-cell lymphoma. , 2014, Biomarkers in medicine.

[11]  T. Kasamatsu,et al.  Nuclear Y-box-binding protein-1 is a poor prognostic marker and related to epidermal growth factor receptor in uterine cervical cancer. , 2014, Gynecologic oncology.

[12]  K. Kuroiwa,et al.  Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer. , 2014, Urologic oncology.

[13]  V. Evdokimova,et al.  The proteolytic YB-1 fragment interacts with DNA repair machinery and enhances survival during DNA damaging stress , 2013, Cell cycle.

[14]  Jie Huang,et al.  Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. , 2013, Journal of the National Cancer Institute.

[15]  K. Kuroiwa,et al.  Mutual Regulation between Raf/MEK/ERK Signaling and Y-Box–Binding Protein-1 Promotes Prostate Cancer Progression , 2013, Clinical Cancer Research.

[16]  H. Izumi,et al.  Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer. , 2012, Clinical lung cancer.

[17]  Y. Sasaguri,et al.  Strong YB‐1 expression is associated with liver metastasis progression and predicts shorter disease‐free survival in advanced gastric cancer , 2012, Journal of surgical oncology.

[18]  A. Bosserhoff,et al.  MAPK and PI3K/AKT mediated YB‐1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop , 2012, Experimental dermatology.

[19]  R. Matkowski,et al.  Elevated Nuclear YB 1 Expression Is Associated with Poor Survival of Patients with Early Breast Cancer , 2012 .

[20]  P. Holm,et al.  Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. , 2011, Anticancer research.

[21]  A. Pollock,et al.  YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. , 2010, Biochemical and biophysical research communications.

[22]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[23]  D. Treue,et al.  Regulation of mRNA expression in drug-sensitive and drug-resistant gastric carcinoma cells is independent of YB-1 expression. , 2010, Anticancer research.

[24]  D. Treue,et al.  Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells. , 2010, Anticancer research.

[25]  M. Kiechle,et al.  Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Dahl,et al.  Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer , 2009, BMC Cancer.

[27]  K. Shirouzu,et al.  Nuclear Y-Box Binding Protein-1, a Predictive Marker of Prognosis, Is Correlated with Expression of HER2/ErbB2 and HER3/ErbB3 in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  P. Tan,et al.  Y-Box-binding protein-1 is a promising predictive marker of radioresistance and chemoradioresistance in nasopharyngeal cancer , 2009, Modern Pathology.

[29]  Samuel Leung,et al.  Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes , 2008, Breast Cancer Research.

[30]  C. Witt,et al.  Nuclear YB‐1 expression as a negative prognostic marker in nonsmall cell lung cancer , 2004, European Respiratory Journal.

[31]  H. Saji,et al.  Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma. , 2003, Cancer letters.

[32]  N. Kinukawa,et al.  Nuclear expression of Y‐box‐binding protein‐1 correlates with P‐glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma , 2003, The Journal of pathology.

[33]  Y. Maehara,et al.  Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.